Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes

You'll start to see more patients withOUT diabetes using SGLT2 inhibitors (Invokana, etc)...for heart failure or kidney disease.

That's because growing evidence suggests these meds may improve outcomes when added to standard therapy...and Canadian heart failure guidelines now recommend it.

In heart failure with reduced ejection fraction (HFrEF), adding Jardiance (empagliflozin) over 16 months prevents hospitalization or CV death in about 1 in 14 type 2s...or 1 in 26 patients withOUT diabetes.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote